Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia

作者：Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally, Joaquín J. Jiménez · 发表于：Oncotarget · 年份：2024 · DOI：10.18632/oncotarget.28579 · 被引用次数：6 · 研究领域：Acute Myeloid Leukemia Research、Neuroblastoma Research and Treatments、Glioma Diagnosis and Treatment

// Simonetta I. Gaumond 1 , Rama Abdin 2 , Joel Costoya 1 , Andrew V. Schally 3 and Joaquin J. Jimenez 1 1 Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 2 Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA 3 Veterans Affairs Medical Center, Miami, FL 33125, USA Correspondence to: Simonetta I. Gaumond, email: sxg1204@miami.edu Keywords: leukemia; AML; resistance; growth hormone-releasing hormone; MIA-602 Received: March 06, 2024     Accepted: March 25, 2024     Published: April 08, 2024 Copyright: © 2024 Gaumond et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin o...